Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000938
Chunk: 6

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 6
---
Act”)). The securities referred to in this Report on Form 6-K are being issued and sold by the Company to the Purchaser in reliance
upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule
506(b) of Regulation D promulgated thereunder. The securities may not be offered or sold in the United States absent registration or an
applicable exemption from registration requirements. Neither this Report on Form 6-K, nor the exhibits attached hereto, is an offer to
sell or the solicitation of an offer to buy the securities described herein.

<div align='center'>SUBMITTED HEREWITH</div>

Attached to the Registrant’s Form 6-K filing for the month of January
2025, and incorporated by reference herein, is:

| * | Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit 
 will be furnished to the SEC upon request.                                                                                           |

| 4 |

<div align='center'>SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

| Date:  January 17, 2025 | Biodexa Pharmaceuticals 
 PLC                     
 By:                     | /s/ Stephen Stamp                 |
|:------------------------|:------------------------|:----------------------------------|
|                         |                         | Stephen Stamp                     |
|                         |                         | Chief Executive Officer and Chief 
 Financial Officer                 |

| 5 |

Exhibit 10.1

<div align='center'>SECURITIES PURCHASE AGREEMENT</div>

THIS SECURITIES PURCHASE AGREEMENT (the “”), dated as of January 17, 2025 (the “”), by and between
BIODEXA PHARMACEUTICALS PLC, a company incorporated under the laws of England and Wales (the “”), and
C/M CAPITAL MASTER FUND, LP, a Delaware limited partnership (the “”).

<div align='center'>WHEREAS:</div>

Subject to the terms and conditions
set forth in this Agreement, the Company wishes to sell to the Investor, and the Investor wishes to buy from the Company, from time to
time and as provided herein, up to Thirty-Five Million Dollars ($35,000,000) of the Company’s American